Genoway (France) Performance
| ALGEN Stock | EUR 3.93 0.09 2.34% |
The company retains a Market Volatility (i.e., Beta) of -0.39, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Genoway are expected to decrease at a much lower rate. During the bear market, Genoway is likely to outperform the market. At this point, Genoway has a negative expected return of -4.0E-4%. Please make sure to check out Genoway's kurtosis, and the relationship between the maximum drawdown and day median price , to decide if Genoway performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Genoway has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, Genoway is not utilizing all of its potentials. The latest stock price agitation, may contribute to short-term losses for the retail investors. ...more
| Total Cashflows From Investing Activities | -2.3 M |
Genoway |
Genoway Relative Risk vs. Return Landscape
If you would invest 398.00 in Genoway on September 1, 2024 and sell it today you would lose (5.00) from holding Genoway or give up 1.26% of portfolio value over 90 days. Genoway is generating negative expected returns and assumes 1.9574% volatility on return distribution over the 90 days horizon. Simply put, 17% of stocks are less volatile than Genoway, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Genoway Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Genoway's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Genoway, and traders can use it to determine the average amount a Genoway's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -2.0E-4
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ALGEN |
Estimated Market Risk
| 1.96 actual daily | 17 83% of assets are more volatile |
Expected Return
| 0.0 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Genoway is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Genoway by adding Genoway to a well-diversified portfolio.
Genoway Fundamentals Growth
Genoway Stock prices reflect investors' perceptions of the future prospects and financial health of Genoway, and Genoway fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Genoway Stock performance.
| Return On Equity | 0.038 | |||
| Return On Asset | 0.0019 | |||
| Profit Margin | 0.03 % | |||
| Operating Margin | 0 % | |||
| Current Valuation | 35.89 M | |||
| Shares Outstanding | 8.19 M | |||
| Price To Earning | 15.31 X | |||
| Price To Book | 2.13 X | |||
| Price To Sales | 1.55 X | |||
| Revenue | 14.02 M | |||
| EBITDA | 1.68 M | |||
| Cash Per Share | 0.52 X | |||
| Total Debt | 8.99 M | |||
| Debt To Equity | 59.10 % | |||
| Book Value Per Share | 1.83 X | |||
| Cash Flow From Operations | (561.34 K) | |||
| Earnings Per Share | 0.05 X | |||
| Total Asset | 32.66 M | |||
| Retained Earnings | (15 M) | |||
| Current Asset | 9 M | |||
| Current Liabilities | 6 M | |||
About Genoway Performance
Assessing Genoway's fundamental ratios provides investors with valuable insights into Genoway's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Genoway is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
genOway S.A., a biotechnology company, engages in the development and sale of custom genetically-modified mouse, rat, and cellular models worldwide. The company was founded in 1999 and is based in Lyon, France. GENOWAY operates under Biotechnology classification in France and is traded on Paris Stock Exchange. It employs 105 people.Things to note about Genoway performance evaluation
Checking the ongoing alerts about Genoway for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Genoway help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Genoway generated a negative expected return over the last 90 days | |
| The company reported the revenue of 14.02 M. Net Loss for the year was (322.6 K) with profit before overhead, payroll, taxes, and interest of 10.2 M. | |
| Genoway has accumulated about 0 in cash with (561.34 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.52. | |
| Roughly 13.0% of the company shares are held by company insiders |
- Analyzing Genoway's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Genoway's stock is overvalued or undervalued compared to its peers.
- Examining Genoway's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Genoway's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Genoway's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Genoway's stock. These opinions can provide insight into Genoway's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Genoway Stock Analysis
When running Genoway's price analysis, check to measure Genoway's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genoway is operating at the current time. Most of Genoway's value examination focuses on studying past and present price action to predict the probability of Genoway's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genoway's price. Additionally, you may evaluate how the addition of Genoway to your portfolios can decrease your overall portfolio volatility.